Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.80 |
| ▸ | MAOB | P27338 | 4/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522668 | 0.81 | ALOX15 (0.70) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL2518549 | 0.81 | ALOX15 (0.89) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL15217627 | 0.81 | KDM4E (0.68) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL2514842 | 0.79 | ALOX15 (1.00) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL5327074 | 0.79 | KDM4E (0.67) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL2521725 | 0.78 | ALOX15 (0.78) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL2516502 | 0.78 | ALOX15 (0.97) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL2519843 | 0.77 | ALOX15 (0.76) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL113766 | 0.76 | MAOA (0.53) | MAOAMAOBALOX15CYP1A2CYP2D6 | |
| SCHEMBL112261 | 0.76 | MAOA (0.53) | MAOAMAOBALOX15CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-03-08 | — | — | US | disclosed |
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-03-08 | — | — | US | disclosed |
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-03-08 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-8058442-B2 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| WO-2010123995-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| EP-1565185-A2 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004041151-A2 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041151-A2 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058945-A1 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FECH, HMOX1, FTH1 | MAOA 1054/4885MAOB 1687/4885ALOX15 591/4885 |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | FECH, HMOX1, FTH1 | MAOA 779/4885MAOB 1223/4885ALOX15 506/4885 |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | MAOA 28/4885MAOB 33/4885ALOX15 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.